share_log

Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81

Benzinga ·  May 9 02:46

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $80 to $81.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment